Effects of endocrine disorders on lipids and lipoproteins

被引：21

作者：

Newman, Connie B. ^{[1
,2
]}

机构：

[1] New York Univ, Div Endocrinol Diabet & Metab, Grossman Sch Med, New York, NY 10016 USA

[2] 550 First Ave, New York, NY 10016 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2023年 / 37卷 / 03期

关键词：

endocrine diseases; lipids; acromegaly; thyroid; cushing; hypogonadism; POLYCYSTIC-OVARY-SYNDROME; LOW-DENSITY-LIPOPROTEIN; CARDIOVASCULAR RISK-FACTORS; GROWTH-HORMONE DEFICIENCY; GH-REPLACEMENT THERAPY; CORONARY-HEART-DISEASE; ESTROGEN PLUS PROGESTIN; BODY-COMPOSITION; INSULIN SENSITIVITY; HEPATIC LIPASE;

D O I：

10.1016/j.beem.2022.101667

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Endocrine diseases may be associated with dyslipidaemia and may increase atherosclerotic cardiovascular disease (ASCVD) risk. This chapter describes changes in lipids and lipoproteins in diseases of the pituitary, thyroid, adrenal glands, ovaries, and testes, the mechanisms for these changes, ASCVD risk in these endocrine disorders, and whether treatment of the endocrine disorder im-proves the lipid profile and reduces ASCVD risk. Acromegaly, GH deficiency, Cushing syndrome, chronic glucocorticoid replacement, hypothyroidism, PCOS and male hypogonadism can increase LDL-C and/or TG. Marked reductions in LDL-C are associated with hy-perthyroidism, and extremely low HDL-C levels with testosterone and/or other anabolic steroid abuse. Acromegaly, GH deficiency, Cushing syndrome, and chronic glucocorticoid replacement are associated with increased ASCVD risk. Treatment of acromegaly, GH deficiency, hypothyroidism, Cushing syndrome, and testos-terone deficiency reduce LDL-C, although statin therapy may still be needed. Effects on ASCVD are not known. (c) 2022 Elsevier Ltd. All rights reserved.

引用

页数：15

共 133 条

[121]

Taylor AH, 1996, J LIPID RES, V37, P2232

[122] Postmenopausal hormone replacement therapy and risk of acute pancreatitis: A population-based case-control study [J].